Actinogen Medical logo

ACW - Actinogen Medical Share Price

A$0.044 0.0  0.0%

Last Trade - 09/04/21

Micro Cap
Market Cap £35.6m
Enterprise Value £28.6m
Revenue £29.1k
Position in Universe 1050th / 1893
Unlock ACW Revenue
Relative Strength (%)
1m +91.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.22%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.050 0.20 0.16 0.092 0.20 0.094 3.00 +13.5%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ActinogenMedical Ltd revenues decreased 72% to A$16K. Net lossdecreased 42% to A$2.4M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Lower net loss reflectsResearch & development expenses decrease of 79% to A$790K(expense), Share-based payment expenses decrease of 10% toA$82K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ACW Revenue Unlock ACW Revenue

Net Income

ACW Net Income Unlock ACW Revenue

Normalised EPS

ACW Normalised EPS Unlock ACW Revenue

PE Ratio Range

ACW PE Ratio Range Unlock ACW Revenue

Dividend Yield Range

ACW Dividend Yield Range Unlock ACW Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ACW EPS Forecasts Unlock ACW Revenue
Profile Summary

Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated March 26, 1999
Public Since October 12, 2007
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,450,787,169
Free Float (0.0%)
Eligible for
ACW Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ACW
Upcoming Events for ACW
Frequently Asked Questions for Actinogen Medical
What is the Actinogen Medical share price?

As of 09/04/21, shares in Actinogen Medical are trading at A$0.044, giving the company a market capitalisation of £35.6m. This share price information is delayed by 15 minutes.

How has the Actinogen Medical share price performed this year?

Shares in Actinogen Medical are currently trading at A$0.044 and the price has moved by 0.124k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Actinogen Medical price has moved by 68.37% over the past year.

What are the analyst and broker recommendations for Actinogen Medical?

Of the analysts with advisory recommendations for Actinogen Medical, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Actinogen Medical is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Actinogen Medical next release its financial results?

Actinogen Medical is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Actinogen Medical dividend yield?

Actinogen Medical does not currently pay a dividend.

Does Actinogen Medical pay a dividend?

Actinogen Medical does not currently pay a dividend.

When does Actinogen Medical next pay dividends?

Actinogen Medical does not currently pay a dividend.

How do I buy Actinogen Medical shares?

To buy shares in Actinogen Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Actinogen Medical?

Shares in Actinogen Medical are currently trading at A$0.044, giving the company a market capitalisation of £35.6m.

Where are Actinogen Medical shares listed? Where are Actinogen Medical shares listed?

Here are the trading details for Actinogen Medical:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ACW
What kind of share is Actinogen Medical?

Based on an overall assessment of its quality, value and momentum, Actinogen Medical is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Actinogen Medical share price forecast 2021?

We were not able to load any forecast data for Actinogen Medical.

How can I tell whether the Actinogen Medical share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actinogen Medical. Over the past six months, the relative strength of its shares against the market has been 45.44%. At the current price of A$0.044, shares in Actinogen Medical are trading at 81.87% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Actinogen Medical PE Ratio?

We were not able to find PE ratio data for Actinogen Medical.

Who are the key directors of Actinogen Medical?

Actinogen Medical's management team is headed by:

Peter Webse - SEC
Geoffrey Brooke - NEC
George Morstyn - NED
Malcolm McComas - NED
Jeff Carter - CFO
Steven Gourlay - CEO
Who are the major shareholders of Actinogen Medical?

Here are the top five shareholders of Actinogen Medical based on the size of their shareholding:

BVF Partners L.P. Hedge Fund
Percentage owned: 14.45% (239.9m shares)
Gourlay (Steve Ph.D.) Individual Investor
Percentage owned: 3.82% (63.4m shares)
Edinburgh Technology Fund Ltd. Corporation
Percentage owned: 2.9% (48.1m shares)
Surfit Capital Pty. Ltd. Corporation
Percentage owned: 2.11% (35.0m shares)
Cameron (Sarah) Individual Investor
Percentage owned: 1.56% (25.9m shares)
Similar to ACW
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.